Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study

被引：0

作者：

Jianqiu Wu

Yongping Song

Liping Su

Li Xu

Tingchao Chen

Zhiyun Zhao

Mingzhi Zhang

Wei Li

Yu Hu

Xiaohong Zhang

Yuhuan Gao

Zuoxing Niu

Ru Feng

Wei Wang

Jiewen Peng

Xiaolin Li

Xuenong Ouyang

Changping Wu

Weijing Zhang

Yun Zeng

Zhen Xiao

Yingmin Liang

Yongzhi Zhuang

Jishi Wang

Zimin Sun

Hai Bai

Tongjian Cui

Jifeng Feng

机构：

[1] Jiangsu Cancer Hospital,

[2] Henan Cancer Hospital,undefined

[3] Shanxi Cancer Hospital,undefined

[4] Shanghai Roche Pharmaceuticals Ltd,undefined

[5] The First Affiliated Hospital of Zhengzhou University,undefined

[6] Jilin University First Affiliated Hospital,undefined

[7] Union Hospital Tongji Medical College Huazhong University of Science and Technology,undefined

[8] The Second Affiliated Hospital of Zhejiang University School of Medicine,undefined

[9] Fourth Hospital of Hebei Medical University,undefined

[10] Affiliated Hospital of Shandong Academy of Medical Sciences,undefined

[11] Nanfang Medical University Nanfang Hospital,undefined

[12] Guangdong Foshan First Hospital,undefined

[13] Guangdong Zhongshan People’s Hospital,undefined

[14] Xiangya Hospital Central South University,undefined

[15] Fuzhou General Hospital of Nanjing Military Command,undefined

[16] Changzhou First People’s Hospital,undefined

[17] 307 Hospital of PLA,undefined

[18] First Affiliated Hospital of Kunming Medical University,undefined

[19] Affiliated hospital of Neimenggu Medical College,undefined

[20] The Fourth Military Medical University Affiliated Tangdu Hospital,undefined

[21] Daqing General Hospital Group Oilfield General Hospital,undefined

[22] Affiliated Hospital of Guiyang Medical College,undefined

[23] Anhui Provincial Hospital,undefined

[24] Lanzhou Military Hospital,undefined

[25] Fujian provincial hospital,undefined

来源：

BMC Cancer | / 16卷

关键词：

DLBCL; R-CHOP; Chemotherapy; HBV infection; HBsAg;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[31] An Escalated Dose of Bortezomib Plus Second Line Chemotherapy for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Jia, Yongqian
Xiang, Bing
Wang, Xiaodong
Li, Jianjun
He, Chuan
Su, Yi
Lu, Hong
Niu, Ting
Huang, Jie
Chen, Xinchuan
Cui, Xu
Gong, Yuping
Zhu, Huanling
Liu, Ting
BLOOD, 2011, 118 (21) : 1587 - 1587
[32] Diffuse large B-cell lymphoma: Which treatment for patients who failed first line treatment?
Coiffier, B.
ANNALS OF ONCOLOGY, 2008, 19 : 81 - 81
[33] Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Thieblemont, Catherine
Tilly, Herve
da Silva, Maria Gomes
Casasnovas, Rene-Olivier
Fruchart, Christophe
Morschhauser, Franck
Haioun, Corinne
Lazarovici, Julien
Grosicka, Anida
Perrot, Aurore
Trotman, Judith
Sebban, Catherine
Caballero, Dolores
Greil, Richard
van Eygen, Koen
Cohen, Amos M.
Gonzalez, Hugo
Bouabdallah, Reda
Oberic, Lucie
Corront, Bernadette
Choufi, Bachra
Lopez-Guillermo, Armando
Catalano, John
Van Hoof, Achiel
Briere, Josette
CabeOadas, Jose
Salles, Gilles
Gaulard, Philippe
Bosly, Andre
Coiffier, Bertrand
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (22) : 2473 - +
[34] Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients
Pejsa, Vlatko
Prka, Zeljko
Lucijanic, Marko
Mitrovic, Zdravko
Pirsic, Mario
Jaksic, Ozren
Ajdukovic, Radmila
Kusec, Rajko
CROATIAN MEDICAL JOURNAL, 2017, 58 (01) : 40 - 48
[35] Metformin prolonged the survival of diffuse large B-cell lymphoma and grade 3b follicular lymphoma patients responding to first-line treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone: a prospective phase II clinical trial
Fan, Xing
Zhong, Hui-Juan
Zhao, Bing-Bing
Yang, Bin-Shen Ou
Zhao, Yan
Ye, Jing
Lu, Yi-Ming
Wang, Chao-Fu
Xiong, Hong
Chen, Sai-Juan
Janin, Anne
Wang, Li
Zhao, Wei-Li
TRANSLATIONAL CANCER RESEARCH, 2018, 7 (04) : 1044 - +
[36] Efficacy Of Rituximab To Chemotherapy In The Treatment Of EBV-Positive Diffuse Large B-Cell Lymphoma
Beltran, Brady E.
Chavez, Julio C.
Castillo, Jorge J.
BLOOD, 2013, 122 (21)
[37] Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
Kayoko Murayama
Toru Kiguchi
Koji Izutsu
Yoshihiro Kameoka
Michihiro Hidaka
Harumi Kato
Shinya Rai
Junya Kuroda
Kenichi Ishizawa
Satoshi Ichikawa
Kiyoshi Ando
Michinori Ogura
Koji Fukushima
Yasuhito Terui
Annals of Hematology, 2022, 101 : 979 - 989
[38] Bevacizumab plus IFN-alpha-2a in First-line Treatment of Patients With Advanced or Metastatic Renal Cell Carcinoma: A Prospective German Non-interventional Study
Schultze-Seemann, Wolfgang
Schulz, Holger
Tschechne, Barbara
Haeckl, Manuel
ANTICANCER RESEARCH, 2019, 39 (02) : 875 - 882
[39] Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
Murayama, Kayoko
Kiguchi, Toru
Izutsu, Koji
Kameoka, Yoshihiro
Hidaka, Michihiro
Kato, Harumi
Rai, Shinya
Kuroda, Junya
Ishizawa, Kenichi
Ichikawa, Satoshi
Ando, Kiyoshi
Ogura, Michinori
Fukushima, Koji
Terui, Yasuhito
ANNALS OF HEMATOLOGY, 2022, 101 (05) : 979 - 989
[40] Phase II study of the tetrahydropyranyl adriamycin--cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma
Kasahara, Senji
Hara, Takeshi
Tsurumi, Hisashi
Goto, Naoe
Kitagawa, Jun-Ichi
Kanemura, Nobuhiro
Yoshikawa, Takeshi
Goto, Hideko
Fukuno, Kenji
Yamada, Toshiki
Sawada, Michio
Takahashi, Takeshi
Takami, Tsuyoshi
Moriwaki, Hisataka
LEUKEMIA & LYMPHOMA, 2011, 52 (04) : 629 - 634

← 1 2 3 4 5 →